A press release from California Trim Clinic, a Westlake Village telemedicine and weight-management practice, says the inclusion of MOTS-c in a new federal compounding framework has changed the conversation around the peptide. The document it points to is real, and so is the distinction the clinic keeps repeating: this is enforcement discretion, not approval.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial DNA, first described in a 2015 Cell Metabolism paper that connected it with metabolic signaling in laboratory and mouse models. A 2018 study reported that the peptide could move into the nucleus under metabolic stress and influence gene expression through an AMPK-dependent process. Both were preclinical.

What the framework actually does

HHS published a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" in the Federal Register on October 30, 2026, covering six substances: MOTS-c, BPC-157, Epitalon, KPV, Semax, and TB-500. It applies while FDA continues formal rulemaking on the 503A Bulks List.

When the specified conditions are met, HHS says it does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities, or licensed physicians compounding products from those substances. For MOTS-c, the framework identifies MOTS-c acetate in subcutaneous or intramuscular injectable dosage forms.

The conditions are the story

This is narrower than a blanket authorization, and the clinic is right to say so. The policy addresses qualifying manufacturers, product documentation, patient-specific prescriptions, reporting requirements, and single-API products.

It also does not place MOTS-c on the final Bulks List, and it does not establish that MOTS-c is safe or effective for obesity, weight loss, insulin resistance, energy, body composition, exercise performance, or longevity. Compounded medications are not FDA-approved, and FDA does not evaluate them for safety, effectiveness, or quality before marketing.

Reading a clinic's press release

The source here is marketing, and it ends with a phone number and a free Discovery Call. What makes it worth reporting is that the regulatory facts in it are stated accurately and the disclaimers are unusually blunt for the genre.

Bottom line

A draft interim policy has given six research-grade peptides a defined compounding lane with guardrails attached. None of that is evidence about what MOTS-c does in people, and the underlying biology is still mouse and cell work.